COMP <GO>
RXST vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
RxSight Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: RXST 2
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $4.87 (-3.56%) • MKT CAP: $210.0M
roic
-14.90%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXST VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXST | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.60% | 74.80% | +1.80 | RXST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -14.90% | 20.70% | -35.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.21% | 3.42% | -12.63 | MRK | /fcf-yield <GO> |
| Operating Margin | -35.80% | 34.30% | -70.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -3.90% | 1.30% | -5.20 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.45 | 5.19 | -3.74 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 51.7 | +0.60 | RXST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $210.0M | $361.02B | -$360.81B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXST REV | MRK REV | RXST GROSS % | MRK GROSS % | RXST FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $134.5M | $65.01B | 76.6% | 74.8% | -$19.3M | $12.36B |
| FY 2024 | $139.9M | $64.17B | 70.7% | 76.3% | -$22.4M | $18.10B |
| FY 2023 | $89.1M | $60.12B | — | — | -$41.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXST // BETA —
MRK // BETA 0.92